Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing
19 July 2022
OHE and the University of Technology Sydney are leading a study funded by the EuroQol Research Foundation to develop a ‘bolt-on’ descriptor for the EQ-5D. The…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
A new publication co-authored by OHE’s David Mott provides an overview of the state of practice for accounting for preference heterogeneity in discrete choice experiments. The…
Severity in Value Assessment: From Principle to Practice
24 March 2022
There is a wealth of evidence showing societal support to prioritise interventions for severe illnesses and a number of robust methods enabling to reflect this in…
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
Carer quality of life impacts can be included in health technology evaluations, however little guidance is provided. NICE considered providing more guidance as part of their…
To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
2 March 2022
This blog post is the second in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
1 March 2022
Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…